Matulon Plus Tablet SR is a sustained-release formulation combining Metformin 500 mg and Myo-Inositol 600 mg, designed to support glycemic control and metabolic health. Metformin, a biguanide antihyperglycemic agent, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, making it a first-line therapy for type 2 diabetes mellitus. The sustained-release mechanism ensures a gradual release of Metformin, minimizing gastrointestinal side effects and enhancing patient compliance. Myo-Inositol, a naturally occurring polyol, plays a crucial role in cellular signaling and insulin signal transduction. Supplementation with Myo-Inositol has been shown to improve insulin sensitivity, particularly in patients with insulin resistance and polycystic ovary syndrome (PCOS), thereby complementing Metformin’s pharmacological effects. Matulon Plus Tablet SR is indicated for the management of type 2 diabetes mellitus and associated metabolic disorders where insulin resistance is a key pathological feature. It may also be beneficial in improving ovulatory function and metabolic parameters in women with PCOS. The combination therapy offers a synergistic approach by targeting multiple pathways involved in glucose homeostasis. Patients should adhere to prescribed dosages and maintain regular monitoring of blood glucose levels. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and to monitor for potential adverse effects.